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Abstract: Crizotinib is a dual MET and ALK inhibitor. Currently,
clinical development of crizotinib is focused primarily on ALK
rearranged non-small cell lung cancer (NSCLC). Here we report an
NSCLC patient with de novo MET amplification but no ALK
rearrangement who achieved a rapid and durable response to crizo-
tinib indicating is also a bona fide MET inhibitor.
Key Words: Non-small cell lung cancer, De novo MET amplifica-
tion NSCLC, 18F-FDG PET/CT, Crizotinib (PF02341066), MET
polysomy, Anaplastic lymphoma kinase (ALK) re-arranged NSCLC.
(J Thorac Oncol. 2011;6: 942–946)
Mutations in the mesenchymal-epithelial transition(MET) gene or increases in MET gene copy number
have been reported and implicated in the pathogenesis of
non-small cell lung cancer (NSCLC).1,2 Recently, MET gene
amplification has been identified as one of the acquired
secondary resistance mechanisms in patients with activating
epidermal growth factor receptor (EGFR) mutations who
progress on EGFR tyrosine kinase inhibitors.3,4 Nevertheless,
true de novo MET amplification as determined by fluores-
cence in situ hybridization (FISH) or quantitative polymerase
chain reaction is rare in NSCLC.5–11 De novo MET amplifi-
cation has been associated with poor outcome,5,6,9,12 but its
significance as a primary oncogenic driver has never been
established in patients with NSCLC. Crizotinib (PF-
02341066) has recently emerged as a potent anaplastic lym-
phoma kinase (ALK) inhibitor; however, it also has signifi-
cant in vitro MET inhibitory activity (IC50 of 8 nm).13
CASE HISTORY
Patient is a 77-year-old white female with a 45 pack
year of smoking history who quit 20 years ago. In October
2008, after a routine chest x-ray, she was noted to have a
mass in the left lung. 18F-fluorodeoxyglucose positron emis-
sion tomography (18F-FDG-PET)/computed tomography
(CT) imaging revealed an FDG-PET-avid 4.0 cm left upper
lobe mass, an FDG-PET-avid 1.3 cm right upper lobe mass,
and additional FDG-PET uptake in the precarinal, aortopul-
monary, and left hilar lymph nodes. CT-guided biopsy of the
left upper lobe mass revealed moderately differentiated ade-
nocarcinoma. Complete staging workup revealed that she had
stage IV NSCLC and was treated with carboplatin/gemcit-
abine/bevacizumab combination chemotherapy every 3
weeks for five cycles. She achieved a partial response and
was switched to maintenance bevacizumab. In March 2010,
she developed a new cough, fatigue, and chest tightness. A
repeat 18F-FDG-PET/CT scan revealed evidence of progres-
sion with enlarging PET-avid subcarinal and left hilar lymph-
adenopathy compared with September 2009. Patient then
decided to seek access to crizotinib through a clinical trial
(A8081001, ClinicalTrials.gov identifier: NCT00585195).
Her tumor tested negative for ALK rearrangement by
break-apart FISH but positive for high-level MET amplifica-
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tion (MET/CEP7 ratio 5.0) (Figure 1), thus meeting the
eligibility criteria for enrollment in the MET-enriched molec-
ular cohort of the A8081001 trial (required to have MET
mutations or MET amplification) (MET/CEP7 ratio2.2; not
polysomy). The patient started crizotinib 250 mg by mouth
twice a day (the recommended phase II dose) in late May
2010. Her symptoms before starting crizotinib included per-
sistent cough, fatigue, and chest tightness. Within a week of
starting crizotinib, her cough disappeared and her fatigue
decreased. A 18F-FDG-PET/CT scan performed 25 days after
starting crizotinib revealed a dramatic 49.3% decrease in
SUVmax from baseline (Figures 2A, B) with a corresponding
35.7% decrease in the maximum aggregate tumor measure-
ment by RECIST (version 1.1) (Figures 3A, B). A follow-up
8-week PET/CT revealed continual response to crizotinib
with a 67.6% decrease in the SUVmax from baseline with a
corresponding 45.2% decrease in tumor measurement by
RECIST (version 1.1). She achieved maximum reduction in
aggregate tumor measurement of 54.8% on September 2010,
and she continues on study with partial response. The only
side effect attributed to crizotinib experienced by the patient
was asymptomatic grade 1 sinus bradycardia and transient
grade 1 visual disturbances characterized by intermittent
flashing lights in the peripheral visual fields. Follow-up visual
acuity and slit-lamp examination revealed no specific retinal
abnormality.
Criteria Determining MET Amplification in
A8081001 Trial
The MET copy number was determined by laboratory-
developed test using a bacterial artificial chromosome probe
containing MET sequence (CTB-13N12) labeled in Spectru-
mOrange and a commercial centromere 7 probe (Vysis/
Abbott Molecular, IL) labeled in SpectrumGreen. Five-mi-
cron sections of formalin-fixed paraffin-embedded tumor
material were prepared and an hematoxylin and eosin section
reviewed to select regions for hybridization that contained a
majority of tumor cells. For each specimen, individual cell
MET and CEP7 signals were analyzed in a total of 50 tumor
cells. FISH-positive groups include (1) high-level amplifica-
tion (presence of loose or tight clusters of MET signals too
numerous to count) or a MET/CEP7 ratio more than 5.0 and
FIGURE 1. Mesenchymal-epithelial transition (MET) amplifi-
cation by fluorescence in situ hybridization (FISH). Tumor
cells show cluster of MET amplified loci represented by a red
aggregate (white arrow). The CEP7 chromosome is repre-
sented by a single blue dot (yellow arrow). Nuclei stained
with 4=,6-diamidino-2-phenylindole.
FIGURE 2. A and B, 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)/computed tomography (CT) fu-
sion image of subcarinal lymph node before starting crizotinib and 25 days after starting crizotinib, respectively.
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FIGURE 3. A and B, Computed tomography (CT) image of subcarinal lymph node before starting crizotinib and 25 days af-
ter starting crizotinib, respectively.
TABLE 1. Prevalence of De Novo MET Amplification in EGFR TKI Naïve Non-small Cell Lung Cancer (NSCLC)
Study qPCR FISH Comments
Bean et al.3 3% (2/16) NA
Criteria for amplification:
MET/MTHFR 5 copies/cell
Okuda et al.5 5.6% (12/213) NA MET amplification found only in male ever smokers
Criteria for amplification: MET/LINE-
1  3 copies/cell
No correlation to histology, stage, or tumor differentiation
Poor prognosis associated with MET amplification
Beau-Faller et al.12 21% (22/106) (-globulin, GAPDH as
internal control)
NA No correlation of MET amplification to sex, histology,
and smoking status
Trend for poorer survival in adenocarcinoma but no
SqCCCriteria for amplification: normalized
ratio over mean plus 2 SD of 30
normal lung DNA samples
Cappuzzo et al.6 NA 4.1%
Criteria for amplification:
5 copies/cell
No correlation of MET amplification to sex, histology,
and smoking status
MET amplification poor prognosis for OS by multivariate
analysis (p  0.04)
Kubo et al.7 2% (2/100) NA
Criteria for amplification: MET/LINE-1
5 copies/cell
Onozato et al.8 1.4% (2/148) NA
Criteria for amplification: MET/LINE-
1  2 copies/cell
Go et al.9 NA 3.9% Poor prognosis of MET amplification in SqCC
(p  0.013)Criteria for amplification:
UCCC criteria
Onitsuka et al.10 4% (8/183) NA No correlation of MET amplification to clinical factors or
HGF expressionCriteria for amplification: 1.31 copies
man MET gene copy measure plus
2X SD in the this study
Camidge et al.11 NA 0% (0/66)
Criteria for amplification:
UCCC criteria
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; HGF, hepatocyte growth factor; LINE-1, long interspersed nuclear element 1; MET,
mesenchymal-epithelial transition; MTHFR, methylenetetrahydrofolate reductase; NA, not applicable; SD, standard deviation; SqCC, squamous cell carcinoma; TKI, tyrosine kinase
inhibitor; UCCC, University of Colorado Cancer Center; qPCR, quantitative polymerase chain reaction.
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(2) low-level amplification (tumors with MET/CEP7 ratio
2.2 and 5.0).
DISCUSSION
This is the first report of rapid and durable clinical
response with single-agent crizotinib in a NSCLC patient
with de novo MET amplification. Furthermore, given this
patient was negative for ALK rearrangement, the beneficial
clinical effect observed in this patient can likely be attributed
to crizotinib’s MET inhibitory property.13 The rapid and
significant clinical response to crizotinib in this patient with
NSCLC with de novo MET amplification mirrored what has
been described for crizotinib’s activity in patients with
NSCLC with ALK rearrangement14,15 and strongly suggests
that de novo MET amplification in NSCLC is likely a primary
oncogenic driver in some NSCLC and is a valid clinical
target. Matsubara et al.16 have shown that MET amplification
alone is a strong predictor of sensitivity to another MET
inhibitor (PHA665752) in NSCLC cell lines.
Going forward, two major challenges exist in exploring
the clinical activity of MET inhibitors in patients with
NSCLC with de novo MET amplification. First, the clinico-
pathologic profile of these patients remains largely unknown.
Review of the literature suggests that in NSCLC, de novo
MET amplification is not specific to any given gender, age
group, histologic subtype, smoking status, or ethnicity.6,7,10,12
As the screening result from A8081001 demonstrates, de
novo MET amplification in NSCLC is rare.3,5,6–11 As of July
25, 2010, we have identified only two patients with NSCLC
with de novo MET amplification out of 94 patients with
NSCLC who had enrolled onto the screening portion of
A8081001 and who had adequate tumor tissue to be success-
fully screened simultaneously for MET amplification and
ALK rearrangement at University of California Irvine. The
other patient with MET amplified (MET/CEP7 ratio 2.5)
NSCLC was a male white never smoker who presented with
stage IIIB squamous cell carcinoma and who has not started
treatment with crizotinib due to response to initial chemora-
diation treatment. For comparison purpose, 15 patients with
ALK-positive NSCLC were identified from the same 94
patients with NSCLC who were screened. Similarly, Univer-
sity of Colorado screened 66 patients with NSCLC (from
June 2008 to October 2009) for both ALK rearrangement and
de novo MET amplification. No patient was positive for MET
amplification, whereas 13 patients were positive for ALK
rearrangement.11 Granted the strategy used by many
A8081001 investigators to screen mostly never smokers with
adenocarcinoma may have skewed the chance of finding
more patients with de novo MET amplification.
Second, guidelines need to be established to define
MET amplification positivity similar to the guidelines estab-
lished for EGFR amplification in NSCLC.17 Different studies
have used different methods and criteria to detect and define
MET amplification (Table 1). A recent retrospective subgroup
analysis of a randomized phase II trial in unselected, EGFR
tyrosine kinase inhibitor-naive patients with NSCLC, pro-
gression-free survival seemed to be most improved in patients
with more than five MET copies by FISH when a MET
inhibitor was combined with erlotinib compared with erlo-
tinib alone.18 This current report provides further evidence
that high-level MET amplification (MET/CEP7 ratio 5) is a
good criterion to select a cohort of patients with molecularly
enriched NSCLC for MET inhibitors in clinical trials. The
significance of low MET amplification or MET high poly-
somy as a predictive marker of response to crizotinib or other
MET inhibitors remains to be determined. One patient with
NSCLC with high MET polysomy (mean MET copy number
per cell, 9.02) but negative for ALK rearrangement or de novo
MET amplification (MET/CEP7 ratio 1.14, 50 nuclei scored)
was treated at University of California Irvine but experienced
disease progression after two cycles (6 weeks) of crizotinib
treatment (unpublished data). A recent clinical trial has
demonstrated using immunohistochemistry (IHC) to strat-
ify for MET protein expression level is another potential
valid method to predict clinical response to a monoclonal
antibody against MET in combination with erlotinib.19 The
degree of concordance between IHC and FISH MET pos-
itivity and whether IHC will eventually be the preferred
method for screening for MET amplification as it is less
technically challenging and more cost-effective warrants
further investigations.
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